Arcus Biosciences, Inc. (RCUS)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$17.69-8.39%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RCUS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.8% |
| Our one-year growth estimate | diamond | -43.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
RCUS — earnings miss
Dated 2026-05-05
of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Arcus reported a preliminary cash balance of $694 million at September 30. The next report will show how much funding remains for its trials.
Worry ifThe November 4 report confirms cash of at least $694 million at September 30.
Less concerning ifThe November 4 report puts September 30 cash below $650 million.
Why it matters: These results test casdatifan with zimberelimab in first-line kidney cancer. They may help shape the planned Phase 3 trial.
Watch forEarly data show tumors shrinking. No new safety issues have been reported.
Also watch forEarly data show few tumor responses or a new safety issue that limits treatment.
Why it matters: AB102 is Arcus's first inflammation drug planned for human testing. A study start would mark a clear step from lab work to clinical development.
Supportive ifArcus reports its first study of AB102 in healthy volunteers has started.
Worry ifArcus reports that the study has not started by its next update, or that it has been delayed.
Why it matters: PRISM-1 tests quemliclustat with standard drugs in first-line pancreatic cancer. The results will show whether the added drug helps patients.
Watch forArcus reports the trial met its main goal, with better results for quemliclustat plus standard drugs.
Also watch forArcus reports the trial missed its main goal or showed no added benefit.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$206 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $641 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,397 loss on $10,000 · 44.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting PEAK-20 would move Arcus's TKI-free kidney cancer plan into a large trial. A delay would push back that key test.
Supportive ifArcus reports PEAK-20 has started by December 31, 2026.
Worry ifPEAK-20 has not started by December 31, 2026, or Arcus reports a delay.